Single ascending dose study of AQW051 in male Caucasians

Trial Profile

Single ascending dose study of AQW051 in male Caucasians

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2013

At a glance

  • Drugs AQW 051 (Primary)
  • Indications Psychotic disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 13 Dec 2013 New trial record
    • 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top